Dermatology
| Atopic Dermatitis
Dermatology
Atopic Dermatitis
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis
book_2
Source:
EADV Congress 2022 - Oral session
calendar_today
Published on Medfyle:
September 2022
import_contacts
4
min
In this medfyle
Registry data suggest that dupilumab dose reduction is successful in a subgroup of patients with controlled AD by using a patient-centered dosing regimen.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a highlights summary of an oral session given at the EADV 2022 - 31st Congress and presented by:
Dr. Lotte Spekhorst
University Medical Center Utrecht
Utrecht, Netherlands
The content is produced by Infomedica, the official reporting partner of EADV 2022.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
